Medicine and Dentistry
Chemotherapy
53%
Malignant Neoplasm
46%
Chemotherapeutic Agent
40%
Drug
40%
Platinum
33%
Ovarian Cancer
26%
Toxicity
26%
Bevacizumab
26%
Woman
26%
Platinum-Resistant Ovarian Cancer
20%
Chemotherapy Regimens
13%
Irinotecan Sucrosofate
13%
Lipid
13%
Treatment Response
13%
Phase II Trials
13%
Surgery
13%
Development
13%
Drug Delivery
13%
Drug Delivery System
13%
Fallopian Tube
13%
Peritoneum
6%
Abdominal Wall
6%
Primary Peritoneal Cancer
6%
Recurrent Disease
6%
Neoplasm
6%
Vascular Bundle
6%
Female Reproductive Tract
6%
Patient
6%
Growth
6%
Therapeutic Procedure
6%
Experience
6%
Diagnosis
6%
Tissues
6%
Combination Therapy
6%
Ovary
6%
Bioavailability
6%
INIS
cancer
100%
ovaries
60%
platinum
53%
chemotherapy
46%
drugs
40%
women
26%
toxicity
26%
layers
20%
lipids
13%
drug delivery
13%
management
13%
surgery
13%
tubes
13%
liposomes
13%
females
6%
peritoneum
6%
tissues
6%
encapsulation
6%
patients
6%
walls
6%
tumors
6%
growth
6%
therapy
6%
biological availability
6%
death
6%
blood vessels
6%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
46%
Drug
40%
Platinum
33%
Ovary Cancer
26%
Toxicity
26%
Bevacizumab
26%
Irinotecan Sucrosofate
13%
Chemotherapy Agent
13%
Lipid
13%
Bioavailability
6%
Recurrent Disease
6%
Neoplasm
6%
Death
6%